CN114005532A - Differentiated thyroid cancer patient postoperative iodine treatment auxiliary decision system - Google Patents
Differentiated thyroid cancer patient postoperative iodine treatment auxiliary decision system Download PDFInfo
- Publication number
- CN114005532A CN114005532A CN202111387238.0A CN202111387238A CN114005532A CN 114005532 A CN114005532 A CN 114005532A CN 202111387238 A CN202111387238 A CN 202111387238A CN 114005532 A CN114005532 A CN 114005532A
- Authority
- CN
- China
- Prior art keywords
- iodine
- treatment
- risk
- patient
- judgment result
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 33
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 title claims abstract description 32
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 229910052740 iodine Inorganic materials 0.000 title claims abstract description 25
- 239000011630 iodine Substances 0.000 title claims abstract description 25
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims abstract description 56
- 238000013517 stratification Methods 0.000 claims abstract description 17
- 230000001575 pathological effect Effects 0.000 claims abstract description 11
- 238000011287 therapeutic dose Methods 0.000 claims description 17
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 11
- 210000001685 thyroid gland Anatomy 0.000 claims description 11
- 238000011156 evaluation Methods 0.000 claims description 10
- 201000002510 thyroid cancer Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 4
- 102000011923 Thyrotropin Human genes 0.000 claims description 4
- 108010061174 Thyrotropin Proteins 0.000 claims description 4
- 230000009545 invasion Effects 0.000 claims description 4
- 210000001165 lymph node Anatomy 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims description 2
- 102000009843 Thyroglobulin Human genes 0.000 claims description 2
- 108010034949 Thyroglobulin Proteins 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 229960002175 thyroglobulin Drugs 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940036571 iodine therapy Drugs 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000004223 overdiagnosis Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
Abstract
The invention provides an auxiliary decision-making system for postoperative iodine treatment of a differentiated thyroid cancer patient, and belongs to the field of auxiliary decision-making systems. The system comprises the following parts: a first part: a data acquisition terminal; is used for collecting clinical data and pathological examination data of a differentiated thyroid cancer patient; a second part: a background server; the background server comprises a recurrence risk degree layering module, and the recurrence risk degree layering module is used for judging the recurrence risk degree of the patient and giving a suggestion whether to carry out iodine-131 treatment according to the judgment result of the recurrence risk degree; and a third part: a user terminal; and the system is used for outputting the judgment result and suggestion of the background server. The postoperative iodine treatment assistant decision making system provided by the invention is based on the postoperative initial recurrence risk stratification of the patient, and sends suggestions to the user according to whether the patient is subjected to iodine-131 treatment or not and the iodine-131 treatment dosage, so that the individual iodine treatment decision making suggestions are provided for the user, and the postoperative iodine treatment assistant decision making system has important significance for clinically assisting in making the treatment decision of the postoperative differentiated thyroid cancer patient.
Description
Technical Field
The invention belongs to the field of an auxiliary decision system, and particularly relates to an auxiliary decision system for postoperative iodine treatment of a differentiated thyroid cancer patient.
Background
Thyroid Cancer (TC) is the most common malignant tumor of the endocrine system, and the incidence rate thereof gradually increases in the world, and the incidence rate of Thyroid cancer in China increases by 20.1% every year. One important reason for the increased incidence of thyroid cancer is the increased diagnostic utility, particularly the use of high resolution ultrasound, which allows many thyroid cancers to be detected and diagnosed early. However, the TC mortality rate does not change obviously along with the increase of the morbidity, which leads to the wide dispute of over-diagnosis and over-treatment of thyroid cancer, and therefore, the research on the problems related to the thyroid cancer is of great significance.
Differentiated Thyroid Cancer (DTC) is the most common type of thyroid cancer, accounting for 90% of thyroid cancers. In recent years, differentiated thyroid cancer has attracted attention because of its increasing incidence year by year. The therapeutic strategies for DTCs include mainly surgery, postoperative selective radioiodine-131 (RAI-131) treatment, and thyroid-stimulating hormone (TSH) inhibition therapy. The survival rate of DTC patients treated by the standard reaches more than 90 percent in 10 years. However, there are still approximately 30% of patients who experience relapse, suggesting that DTC patients have a non-trivial risk of relapse. To assess the risk of postoperative recurrence in patients, the American Thyroid Association (ATA) guidelines, 2015 edition, decided to stratify DTC patients into risk of postoperative recurrence, into high, medium, and low risk stratification, and further guide iodine treatment and selection of doses thereof. The initial risk stratification of ATA is also a common evaluation index in clinical practice at present.
Chinese patent application No. 202010548101.8 discloses a self-service evaluation system after surgery suitable for differentiated thyroid cancer patients, which comprises a data acquisition terminal, a background server and a patient terminal. The background server is used for carrying out initial and dynamic relapse risk assessment and endocrine suppression (drug) treatment scheme assessment processing according to patient data and sending suggestions to the patient terminal. The system can conveniently provide postoperative risk self-service evaluation for the differentiated thyroid cancer patients, and solves the problems that the differentiated thyroid cancer patients need to be subjected to repeated investigation, diagnosis and medicine adjustment every year after operation, and a large amount of time and economic cost are consumed; the problems that the large-scale three hospitals are difficult to review and register and the related professional knowledge of primary hospitals is lack of and difficult to meet the review requirement due to serious shortage of specialists in thyroid surgery are solved; the problem of insufficient normalization degree of postoperative endocrine inhibition treatment of domestic differentiated thyroid cancer patients is solved by adopting a normalized and standardized treatment scheme. However, the system cannot give advice on whether to perform iodine-131 treatment and iodine-131 treatment dosage for patients with differentiated thyroid cancer.
It is important to develop an aid decision system which can give advice on whether to perform iodine-131 treatment and the iodine-131 treatment dosage for patients with differentiated thyroid cancer.
Disclosure of Invention
The invention aims to provide a postoperative iodine treatment aid decision-making system which can give a recurrence risk judgment result for a differentiated thyroid cancer patient, and can give a suggestion on whether to perform iodine-131 treatment and iodine-131 treatment dosage.
The invention provides an auxiliary decision-making system for postoperative iodine treatment of a differentiated thyroid cancer patient, which comprises the following parts:
a first part: a data acquisition terminal; is used for collecting clinical data and pathological examination data of a differentiated thyroid cancer patient;
a second part: a background server; the background server comprises a recurrence risk degree layering module, and the recurrence risk degree layering module is used for judging the recurrence risk degree of the patient and giving a suggestion whether to carry out iodine-131 treatment according to the judgment result of the recurrence risk degree;
and a third part: a user terminal; and the system is used for outputting the judgment result and suggestion of the background server.
Further, in the first section, the clinical data includes sex, age, thyroidectomy mode, cervical lymph node clearing range, whether the lesion is completely removed;
the pathological examination data comprise tumor pathological types, external invasion of the external thyroid tissue by the tumor, affected external thyroid soft tissue, follicular cancer blood vessel invasion, lymph node metastasis quantity, maximum diameter of metastatic lymph nodes, distant metastasis and postoperative rechecking indexes.
Further, in the first section, the postoperative follow-up index includes thyroid stimulating hormone, thyroglobulin antibody, and cervical color ultrasound conclusion.
Further, in the second section, the judgment result of the recurrence risk is: (1) the information for risk stratification is insufficient, and further special assessment is suggested; (2) high risk; (3) low risk; or (4) medium risk.
Further, in the second section, when the judgment result of the recurrence risk is that the information for risk stratification is insufficient and further specialist evaluation is recommended, the recommendation whether to perform iodine-131 treatment is given as follows: if the information is insufficient, further special assessment is suggested;
when the judgment result of the recurrence risk degree is high risk, the suggestion whether to carry out iodine-131 treatment is given as follows: iodine-131 treatment is recommended;
when the judgment result of the recurrence risk degree is low risk, the suggestion whether to carry out iodine-131 treatment is given as follows: iodine-131 treatment may not be considered;
when the judgment result of the recurrence risk degree is middle risk, the suggestion whether to carry out iodine-131 treatment is given as follows: the decision of whether to perform iodine-131 treatment can be combined with self-willingness and specialist evaluation.
Further, in the second section, the risk of relapse is judged according to the guidelines of the american thyroid association, 2015 edition.
Further, in the second part, the background server further includes an iodine-131 therapeutic dose judgment module, and the iodine-131 therapeutic dose judgment module gives a suggestion of the iodine-131 therapeutic dose by combining the judgment result of the recurrence risk and clinical data and pathological examination data of the patient.
Further, in the second section, the recommendation of the iodine-131 therapeutic dose is given according to the following criteria in order, and the recommendation of the iodine-131 therapeutic dose is given according to the following criteria in order of decreasing logical priority:
when the judgment result of the recurrence risk is that the information for risk stratification is insufficient and further specialist evaluation is recommended, the recommendation of iodine-131 treatment dose is given as follows: if the information is insufficient, further special assessment is suggested;
when the judgment result of the recurrence risk is low risk and the patient is more than 18 years old, the recommendation of iodine-131 treatment dose is given as follows: 30 mCi;
when the judgment result of the recurrence risk is medium-risk and the patient is older than 18 years, the recommendation of iodine-131 treatment dose is given as follows: 30-100 mCi;
when the judgment result of the recurrence risk degree is high risk, distant metastasis occurs, and the patient is more than 18 years old, the proposal of iodine-131 treatment dose is given as follows: 100-250 mCi;
when the judgment result of the recurrence risk is high-risk and the patient is more than 18 years old, the recommendation of iodine-131 treatment dose is given as follows: 150 mCi;
when the patient is less than or equal to 18 years of age, recommendations for iodine-131 therapeutic doses are given as: 1.0 to 1.5 mCi/kg. Further, in the second section, the iodine-131 therapeutic dose judgment module provides a recommendation for iodine-131 therapeutic dose as specified in the american thyroid association guidelines, 2015 edition.
The invention also provides an auxiliary decision-making device for the postoperative iodine treatment of a differentiated thyroid cancer patient, which comprises the prediction system.
The postoperative iodine treatment assistant decision system of the invention is based on the patient postoperative initial recurrence risk stratification, and is used for sending suggestions to the user according to whether the patient is subjected to iodine-131 treatment or not and the iodine-131 treatment dosage. The users of the postoperative iodine treatment assistant decision system are mainly specialists and patients, and the assistant decision system can provide individualized iodine treatment decision suggestions for the users.
The system provided by the invention is simple in construction method, and has important significance in clinically assisting in making treatment decisions of postoperative differentiated thyroid cancer patients.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
Fig. 1 is a schematic diagram of an iodine therapy aid decision system for a differentiated thyroid cancer patient after surgery according to example 1.
Detailed Description
The raw materials and equipment used in the invention are known products and are obtained by purchasing commercial products.
Example 1 differentiated thyroid cancer patient postoperative iodine treatment aid decision making system
The schematic diagram of the differentiated thyroid cancer patient postoperative iodine treatment aid decision-making system of the embodiment is shown in fig. 1, and consists of the following three parts:
a first part: data acquisition terminal
The data acquisition terminal is used for acquiring clinical data and pathological examination data of a differentiated thyroid cancer patient and uploading the personal data, operation data and pathological examination data to the background server, and the data acquisition terminal can be but is not limited to a computer or a mobile phone and the like; when the data acquisition terminal is a computer, the medical staff can operate the computer to input the data of the patient; when the data acquisition terminal is a mobile phone, medical staff can register and enter clinical data of a patient in a login APP or applet mode. The collected data are detailed in Table 1.
TABLE 1 description of the data collected
A second part: background server
The background server comprises the following two modules:
1. recurrence risk stratification module
According to the regulation of the national thyroid association (ATA) guideline of 2015 edition, carrying out initial recurrence risk stratification on patients with differentiated thyroid cancer, wherein the patients are divided into low-risk, medium-risk and high-risk patients; if the relevant information for the stratification is insufficient, "the information for the risk stratification is insufficient, and further professional evaluation is suggested" is further output. The specific hierarchical logic is shown in table 2. And then further outputting a recommendation whether to treat the iodine or not according to the initial risk stratification. The logic for a specific iodine treatment recommendation is shown in table 3.
TABLE 2 logic for initial recurrence Risk stratification
TABLE 3 logic to output advice relevant to iodine therapy
2. Iodine-131 therapeutic dose judging module
For the patients judged to be recommended to be treated by the iodine-131 after operation in the previous step, the recommended treatment dose range is output according to relevant regulations of ATA guidelines, and the specific recommendation is shown in the table 4.
TABLE 4 logic for delivery of iodine therapeutic doses
Note: the logical priority levels from 1 to 6 indicate that the logical priority levels are sequentially lower.
And a third part: user terminal
And sending the result in the background server to the user terminal.
In conclusion, the invention provides an auxiliary decision-making system for postoperative iodine treatment of patients with differentiated thyroid cancer. The postoperative iodine treatment assistant decision making system provided by the invention is based on the postoperative initial recurrence risk stratification of the patient, and sends suggestions to the user according to whether the patient is subjected to iodine-131 treatment or not and the iodine-131 treatment dosage, so that the individual iodine treatment decision making suggestions are provided for the user, and the postoperative iodine treatment assistant decision making system has important significance for clinically assisting in making the treatment decision of the postoperative differentiated thyroid cancer patient.
Claims (10)
1. A differentiated thyroid cancer patient postoperative iodine treatment aid decision-making system is characterized in that: the system shown comprises the following parts:
a first part: a data acquisition terminal; is used for collecting clinical data and pathological examination data of a differentiated thyroid cancer patient;
a second part: a background server; the background server comprises a recurrence risk degree layering module, and the recurrence risk degree layering module is used for judging the recurrence risk degree of the patient and giving a suggestion whether to carry out iodine-131 treatment according to the judgment result of the recurrence risk degree;
and a third part: a user terminal; and the system is used for outputting the judgment result and suggestion of the background server.
2. The system of claim 1, wherein: in the first section, the clinical data include sex, age, thyroidectomy mode, cervical lymph node clearing range, whether the lesion is completely removed;
the pathological examination data comprise tumor pathological types, external invasion of the external thyroid tissue by the tumor, affected external thyroid soft tissue, follicular cancer blood vessel invasion, lymph node metastasis quantity, maximum diameter of metastatic lymph nodes, distant metastasis and postoperative rechecking indexes.
3. The system of claim 2, wherein: in the first section, the postoperative follow-up indicators include thyroid stimulating hormone, thyroglobulin antibodies, and cervical polychrome conclusions.
4. The system of claim 1, wherein: in the second section, the judgment result of the recurrence risk is: (1) the information for risk stratification is insufficient, and further special assessment is suggested; (2) high risk; (3) low risk; or (4) medium risk.
5. The system of claim 4, wherein: in the second section, when the judgment result of the recurrence risk is that the information for risk stratification is insufficient and further specialist evaluation is recommended, the recommendation whether to perform iodine-131 treatment is given as follows: if the information is insufficient, further special assessment is suggested;
when the judgment result of the recurrence risk degree is high risk, the suggestion whether to carry out iodine-131 treatment is given as follows: iodine-131 treatment is recommended;
when the judgment result of the recurrence risk degree is low risk, the suggestion whether to carry out iodine-131 treatment is given as follows: iodine-131 treatment may not be considered;
when the judgment result of the recurrence risk degree is middle risk, the suggestion whether to carry out iodine-131 treatment is given as follows: the decision of whether to perform iodine-131 treatment can be combined with self-willingness and specialist evaluation.
6. The system of claim 5, wherein: in the second section, the risk of relapse is judged according to the guidelines of the american thyroid association, 2015 edition.
7. The system of claim 6, wherein: in the second part, the background server further comprises an iodine-131 therapeutic dose judgment module, and the iodine-131 therapeutic dose judgment module gives a suggestion of iodine-131 therapeutic dose by combining the judgment result of the recurrence risk and clinical data and pathological examination data of the patient.
8. The system of claim 7, wherein: in the second part, the recommendations for iodine-131 therapeutic doses are based on the following criteria, which are sequentially decreasing in logical priority order:
when the judgment result of the recurrence risk is that the information for risk stratification is insufficient and further specialist evaluation is recommended, the recommendation of iodine-131 treatment dose is given as follows: if the information is insufficient, further special assessment is suggested;
when the judgment result of the recurrence risk is low risk and the patient is more than 18 years old, the recommendation of iodine-131 treatment dose is given as follows: 30 mCi;
when the judgment result of the recurrence risk is medium-risk and the patient is older than 18 years, the recommendation of iodine-131 treatment dose is given as follows: 30-100 mCi;
when the judgment result of the recurrence risk degree is high risk, distant metastasis occurs, and the patient is more than 18 years old, the proposal of iodine-131 treatment dose is given as follows: 100-250 mCi;
when the judgment result of the recurrence risk is high-risk and the patient is more than 18 years old, the recommendation of iodine-131 treatment dose is given as follows: 150 mCi;
when the patient is less than or equal to 18 years of age, recommendations for iodine-131 therapeutic doses are given as: 1.0 to 1.5 mCi/kg.
9. The system of claim 8, wherein: in the second section, the iodine-131 therapeutic dose decision module provides recommendations for iodine-131 therapeutic doses as specified in the american thyroid association guidelines, version 2015.
10. The utility model provides a differentiation type thyroid cancer patient iodine treatment aid decision-making equipment that postoperative which characterized in that: the apparatus comprising a prediction system as claimed in any one of claims 1 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111387238.0A CN114005532A (en) | 2021-11-22 | 2021-11-22 | Differentiated thyroid cancer patient postoperative iodine treatment auxiliary decision system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111387238.0A CN114005532A (en) | 2021-11-22 | 2021-11-22 | Differentiated thyroid cancer patient postoperative iodine treatment auxiliary decision system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114005532A true CN114005532A (en) | 2022-02-01 |
Family
ID=79929724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111387238.0A Pending CN114005532A (en) | 2021-11-22 | 2021-11-22 | Differentiated thyroid cancer patient postoperative iodine treatment auxiliary decision system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114005532A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117877721A (en) * | 2024-03-12 | 2024-04-12 | 天津市肿瘤医院（天津医科大学肿瘤医院） | Endocrine treatment management system after personalized thyroid cancer radiotherapy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110634573A (en) * | 2019-09-27 | 2019-12-31 | 南昌大学第一附属医院 | Clinical cerebral infarction patient recurrence risk early warning scoring visualization model system and evaluation method thereof |
| CN112614594A (en) * | 2020-12-25 | 2021-04-06 | 樊友本 | Differentiation type thyroid cancer postoperative follow-up assessment drug-mixing auxiliary system and method |
| WO2021091130A1 (en) * | 2019-11-08 | 2021-05-14 | 가톨릭대학교산학협력단 | Biomarker composition for diagnosing or predicting prognosis of thyroid cancer, comprising preparation capable of detecting mutation in plekhs1 gene, and use thereof |
| CN113130083A (en) * | 2021-05-08 | 2021-07-16 | 中国医学科学院北京协和医院 | Pancreatic neuroendocrine tumor recurrence prediction system, method, terminal and medium |
-
2021
- 2021-11-22 CN CN202111387238.0A patent/CN114005532A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110634573A (en) * | 2019-09-27 | 2019-12-31 | 南昌大学第一附属医院 | Clinical cerebral infarction patient recurrence risk early warning scoring visualization model system and evaluation method thereof |
| WO2021091130A1 (en) * | 2019-11-08 | 2021-05-14 | 가톨릭대학교산학협력단 | Biomarker composition for diagnosing or predicting prognosis of thyroid cancer, comprising preparation capable of detecting mutation in plekhs1 gene, and use thereof |
| CN112614594A (en) * | 2020-12-25 | 2021-04-06 | 樊友本 | Differentiation type thyroid cancer postoperative follow-up assessment drug-mixing auxiliary system and method |
| CN113130083A (en) * | 2021-05-08 | 2021-07-16 | 中国医学科学院北京协和医院 | Pancreatic neuroendocrine tumor recurrence prediction system, method, terminal and medium |
Non-Patent Citations (2)
| Title |
|---|
| 李继勇等: "分化型甲状腺癌术后复发转移的监测指标及影响因素分析", 《中国临床研究》 * |
| 王先明等: "分化型甲状腺癌的风险评估和个体化治疗策略", 《医学与哲学(B)》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117877721A (en) * | 2024-03-12 | 2024-04-12 | 天津市肿瘤医院（天津医科大学肿瘤医院） | Endocrine treatment management system after personalized thyroid cancer radiotherapy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aminian et al. | Association of bariatric surgery with cancer risk and mortality in adults with obesity | |
| Kulasingam et al. | Potential health and economic impact of adding a human papillomavirus vaccine to screening programs | |
| Cleeland et al. | Assessing the symptoms of cancer using patient-reported outcomes (ASCPRO): searching for standards | |
| Buys et al. | Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial | |
| Clark et al. | Changes in quality of life following treatment for early prostate cancer | |
| Yeung et al. | Use and cost of actinic keratosis destruction in the Medicare Part B fee-for-service population, 2007 to 2015 | |
| US20030125988A1 (en) | Patient data mining with population-based analysis | |
| Voineskos et al. | Measuring patient-reported outcomes: key metrics in reconstructive surgery | |
| Valderas et al. | Measuring patient-reported outcomes: moving from clinical trials into clinical practice | |
| EP3077933A1 (en) | Computational medical treatment plan method and system with mass medical analysis | |
| CN104537592A (en) | Self-diagnosis and preventive care guide system | |
| Talluri et al. | Assessment of trends in cigarette smoking cessation after cancer diagnosis among US adults, 2000 to 2017 | |
| Nixon et al. | Cost-effectiveness of symptom monitoring with patient-reported outcomes during routine cancer treatment | |
| CN106874632A (en) | Slow disease health index intelligent monitoring system | |
| Waisbrod et al. | Assessment of diagnostic yield of cystoscopy and computed tomographic urography for urinary tract cancers in patients evaluated for microhematuria: a systematic review and meta-analysis | |
| CN114005532A (en) | Differentiated thyroid cancer patient postoperative iodine treatment auxiliary decision system | |
| Dagovic et al. | Resource use and costs of newly diagnosed cancer initial medical care | |
| Cokkinides et al. | Trends in melanoma mortality among non-Hispanic whites by educational attainment, 1993-2007 | |
| CN110060748A (en) | A kind of multidisciplinary PICC sets pipe assessment managing device and method | |
| Tani et al. | Health information technologies in systemic lupus erythematosus: focus on patient assessment | |
| CN111430045A (en) | Electronic follow-up management system for ankylosing spondylitis patients | |
| CN106264599A (en) | A kind of wisdom stethoscope with identification | |
| Murray et al. | The case for observational management of suspected small choroidal melanoma | |
| CN116013505A (en) | Medical expense management system based on DRG | |
| Fleischer et al. | Are patients' chief complaints generally specific to one organ system? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220201 |
|
| RJ01 | Rejection of invention patent application after publication |